Author:
Olayanju Olatunde,Esmail Aliasgar,Limberis Jason,Dheda Keertan
Abstract
There are limited data on combining delamanid and bedaquiline in drug-resistant tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV-infected persons, are unavailable.We prospectively followed up 122 South African patients (52.5% HIV-infected) with DR-TB and poor prognostic features between 2014 and 2018. We examined outcomes and safety in those who received a bedaquiline-based regimen (n=82) compared to those who received a bedaquiline–delamanid combination regimen (n=40).There was no significant difference in 6-month culture conversion (92.5% versus 81.8%; p=0.26) and 18-month favourable outcome rate (63.4% versus 67.5%; p=0.66) in the bedaquiline versus the bedaquiline–delamanid combination group, despite the latter having more advanced drug resistance (3.7% versus 22.5% resistant to at least five drugs; p=0.001) and higher pre-treatment failure rates (12.2% versus 52.5% with pre-treatment multidrug-resistant TB therapy failure; p<0.001). Although the proportion of prolongation of the QT interval corrected using Fridericia's formula was higher in the combination group (>60 ms from baseline (p=0.001) or >450 ms during treatment (p=0.001)), there were no symptomatic cases or drug withdrawals in either group. Results were similar in HIV-infected patients.A bedaquiline–delamanid combination regimen showed comparable long-term safety compared to a bedaquiline-based regimen in patients with DR-TB, irrespective of HIV status. These data inform regimen selection in patients with DR-TB from TB-endemic settings.
Funder
South African Medical Research Council
European and Developing Countries Clinical Trials Partnership
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference26 articles.
1. Global Tuberculosis Report 2018. Geneva, World Health Organization, 2018.
2. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis;Dheda;Lancet Respir Med,2017
3. Tuberculosis
4. WHO Position Statement on the Use of Delamanid for Multidrug-Resistant Tuberculosis. Geneva, World Health Organization, 2018.
5. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva, World Health Organization, 2019.
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献